BPG is committed to discovery and dissemination of knowledge
Minireviews
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Transl Med. Sep 28, 2026; 12(3): 124147
Published online Sep 28, 2026. doi: 10.5528/wjtm.124147
Perspectives on the bioenergetic dysregulation in insulin-resistant patients comorbid with cancer
Dina Johar, Khaled Mahmoud, Samy Zaky
Dina Johar, Department of Biochemistry and Nutrition, Faculty of Women for Arts, Sciences and Education, Ain Shams University, Cairo 11757, Egypt
Khaled Mahmoud, Department of Pharmacognosy, National Research Centre, Giza 12622, Egypt
Samy Zaky, Hepatogastroenterology and Infectious Diseases Department, Faculty of Medicine, Al-Azhar University, Cairo 11651, Egypt
Author contributions: Johar D contributed to the conception and design of the study, interpretation of literature data, writing, and generation of graphs; Mahmoud K contributed to revisions; Johar D, Mahmoud K, and Zaky S contributed to discussion and review of the manuscript; Mahmoud K and Zaky S contributed to supervision; and Zaky S contributed to administration; All authors have read and approved the final manuscript.
AI contribution statement: No AI tool was involved in the generation of research data, interpretation of results, or formulation of conclusions.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Dina Johar, PhD, Department of Biochemistry and Nutrition, Faculty of Women for Arts, Sciences and Education, Ain Shams University, Asma Fahme Street, Heliopolis, Cairo 11757, Egypt. dinajohar@gu.edu.eg
Received: June 9, 2026
Revised: July 19, 2026
Accepted: August 10, 2026
Published online: September 28, 2026
Processing time: 87 Days and 16.1 Hours
Core Tip

Core Tip: This perspective proposes that among patients with cancer, those with insulin resistance exhibit reduced platelet mitochondrial bioenergetics compared with cancer patients without insulin resistance or healthy controls and that platelet mitochondrial profiling may serve as an early marker of mitochondrial dysfunction in this population. It further hypothesizes that dipeptidyl peptidase 4 inhibition may ameliorate insulin resistance in cancer patients and proposes a cell culture model to test this hypothesis. The article’s clinical relevance lies in potentially identifying non-invasive biomarkers for metabolic dysfunction in patients with cancer and exploring dipeptidyl peptidase 4 (DPP4) inhibitors as therapeutics. Strengths include the integration of cancer biology, metabolic syndrome pathophysiology, and mitochondrial bioenergetics and the proposal of testable frameworks.

Write to the Help Desk